발생일자 2015.04.02 

사건번호 3:15-cv-02384 

법원국가 UNITED STATES OF AMERICA 

관할법원명 D.C.NewJersey(지방법원) 

침해권리 특허 

원고명 Merck Sharp & Dohme Corp. ( 미국 / 외국기업 )  

피고명 Apotex, Inc./ Apotex Corp. ( 캐나다 / 외국기업 )  

소송유형 침해금지 

[Merck Sharp & Dohme Corp. v. Apotex, Inc. et al] 사건번호 3:15-cv-02384에 따르면 원고 Merck Sharp & Dohme Corp.는 피고 Apotex, Inc./ Apotex Corp.을 상대로 특허 US6127353을 침해하였다는 이유로 미국 뉴저지 지방법원에 소를 제기하였다. 

분쟁결과 분쟁중 

산업분류 화학∙바이오 > 의약품 

계쟁제품 Generic version of Nasonex mometasone furoate nasal spray 

지재권번호/명칭

US6127353   Mometasone furoate monohydrate, process for making same and pharmaceutical compositions 

The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound. 

1. 9.alph a.,21-dichloro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.-diol-3,2 0-dione-17-(2'-furoate) monohydrate. 

2. A pharmaceutical composition comprising an antiinflammatory amount of mometasone furoate monohydrate in a pharmaceutically acceptable carrier. 

3. The composition of claim 2, further comprising the following ingredients: 

4. The composition of claim 3 comprising 0.5 mg of mometasone furoate 

 monohydrate. 

5. The compound 9.alpha.,21-dichloro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.-d iol-3,20 dione-17-(2'-furoate) monohydrate exhibiting a x-ray crystallographic powder diffraction pattern having essentially the following values: 

6. A pharmaceutical composition comprising mometasone furoate monohydrate in a carrier consisting essentially of water. 

7. The pharmaceutical composition of claim 6 wherein said mometasone furoate monohydrate is present in an amount of from about 0.1 mg. to about 10.0 mg per gram of water. 

8. The pharmaceutical composition of claim 6 wherein said mometasone furoate monohydrate is present in the form of micronized particles. 

9. The pharmaceutical composition of claim 6 wherein said composition has a pH of from about 4.0 to 5.0. 

10. The pharmaceutical composition of claim 6 further comprising one or more additional components selected from the group consisting essentially of excipients, suspending agents, buffers, surfactants, preservatives and mixtures thereof. 

11. The pharmaceutical composition of claim 6 formulated as a nasal spray. 

12. The pharmaceutical composition of claim 6 wherein said mometasone furoate monohydrate is suspended in said aqueous carrier.